Recently, several studies have reported promising results of neoadjuvant chemotherapy combined with programmed cell death 1 (PD‐1) blockade, which achieved significant tumor regression and low perioperative mortality.4, 5. The gene discussed is PDCD1; the disease is neoplasm.